Big recovery moves when it hits the bottom trend line last two times, about to do the same a third time. Probably a coincidence, but both of the previous take downs were followed by some good news. It wouldn't be too surprising if someone out there knows something we don't and is trying to shake out weak hands to get cheap shares. Expecting this to be $90+...
Repatha (AMGN) and Praluent (Regeneron (REGN)/Sinofy (SNY)) are two PCSK9 inhibitors, a new class of drugs to treat hypercholesterolemia more effectively than previously possible. This will trigger a HCV-like battle between the two as both have high efficacy. Both have room to share the market, allowing both to make a significant amount of money on these...
3 month flag setup and it's finally stepping out of that trend today. We should see it head to around $40, pullback a little bit, and then breakout for new all time highs. Alternatively, a more optimistic look would be "W" pattern and it breaks out when it hits $40 without the pullback.
Approval for Solithromycin is expected in mid-2016. At $1.6B market cap, it...
Two weeks of consolidation in the $66-67 range, coupled with previous waves of consolidation in this area at or below this level since the beginning of the year. The current flag setup is converging at the trend lines and algo programs are likely picking this up as well. This will lead to some action by the end of the week, although without news, it will be...
